Physician

Yuval Raizen, MD

According to 2025 Medicare claims, Yuval Raizen, MD (NPI: 1639339153) practices hematology/oncology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Harris, TX. This provider's primary affiliated billing organization is ONCOLOGY CONSULTANTS, P. A. (NPI: 1679533418; TIN: 760605200) and primary practice location at 77030-3305. Raizen is affiliated with the Main Street Rural Health Hickory ACO LLC (ACO ID: A5334) and Accountable Care Coalition of Southeast Texas, Inc. (ACO ID: D0112), participating under both the MSSP and REACH models.

Raizen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 562 traditional Medicare patients, billed 240,960 HCPCS/CPT codes, and received $4,045,489 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,353 prescription claims across 413 beneficiaries totaling $6,327,523 in drug costs, led by Revlimid (Lenalidomide). DME data shows 15 claims. Open Payments data shows 55 records totaling $1,254. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,181,948 to $4,045,489. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,007,149 to $6,327,523. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	271	105,300	$1,181,948
2016	318	88,255	$1,090,970
2017	339	101,474	$1,375,470
2018	381	116,042	$1,609,046
2019	453	146,670	$1,870,345
2020	439	167,228	$2,565,962
2021	460	179,401	$2,764,175
2022	525	212,677	$3,632,929
2023	537	272,268	$4,006,729
2024	562	240,960	$4,045,489

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	205	1,351	$1,007,149
2016	232	1,414	$1,394,411
2017	253	1,616	$1,886,614
2018	326	2,050	$3,818,765
2019	357	2,434	$5,633,591
2020	391	2,670	$7,453,702
2021	411	2,771	$7,385,325
2022	414	2,802	$7,466,353
2023	409	2,399	$5,261,719
2024	413	2,353	$6,327,523

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	123	$35,039
2016	N/R	39	$3,154
2017	N/R	N/R	N/R
2018	N/R	65	$16,220
2019	N/R	17	$5,050
2020	N/R	116	$62,931
2021	N/R	72	$6,583
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	15	$790

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	460	1,214	$89
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	87	243	$44
80047	Blood test, basic group of blood chemicals (calcium, ionized)	239	546	$13
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	371	611	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	458	1,438	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,309	$849,367
Xtandi	Enzalutamide	36	1,320	$588,284
Verzenio	Abemaciclib	31	868	$465,315
Bosulif	Bosutinib	23	690	$412,500
Erleada	Apalutamide	28	840	$404,771

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$790

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	55	$1,254	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Yuval Raizen, MD?

Tedicare shows public-source Medicare data for Yuval Raizen, MD (NPI 1639339153), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Yuval Raizen, MD have ACO affiliation data?

Yuval Raizen, MD is shown with ACO affiliation data for Main Street Rural Health Hickory ACO LLC (MSSP, ACO ID A5334) and Accountable Care Coalition of Southeast Texas, Inc. (REACH, ACO ID D0112).

What billing organization is linked to Yuval Raizen, MD?

Yuval Raizen, MD is linked to ONCOLOGY CONSULTANTS, P. A. (billing NPI 1679533418) in the available physician profile data.

Does Yuval Raizen, MD have Open Payments data?

Yuval Raizen, MD has 55 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.